NL-OMON48579撤回2 期
An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials - BI655130 in ulcerative colitis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Male or female patients, aged >=18 years;
- •2. Signed and dated written informed consent for 1368.17, in accordance with GCP and local legislation prior to admission into the trial;
- •3. Women of childbearing potential (WOCBP) and men able to father a child must be ready to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information;
- •Note: A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tuba ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause;
- •4. Have completed treatment and the EOT visit in the previous trial and are willing and able to continue treatment in 1368.17.
排除标准
- •1. Have experienced study treatment-limiting adverse events during induction treatment with study drug;
- •2. Have developed any of the exclusion criteria from the original induction study
研究者
相似试验
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-NOBoehringer Ingelheim Norway KS79
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-BESCS Boehringer Ingelheim Comm. V160
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-PLBoehringer Ingelheim RCV GmbH&Co. KG160
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-ESBoehringer Ingelheim España, S.A.160
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-ATBoehringer Ingelheim RCV GmbH&Co. KG160